```html

Insulinoma – A Complete Patient‑Friendly Guide

Overview

Insulinoma is a rare, typically benign tumor that arises from the β‑cells of the pancreas, the cells that produce insulin. Because the tumor releases insulin in an uncontrolled fashion, patients experience episodes of low blood glucose (hypoglycemia). Most insulinomas are solitary, small (<2 cm), and non‑cancerous, but a small proportion can be malignant and spread to nearby lymph nodes or the liver.

Who it affects: Insulinomas can develop at any age, but the highest incidence is seen in adults between 30 and 60 years. Women are slightly more often diagnosed than men (approximately 55 % vs. 45 %). They are also the most common cause of endogenous hyperinsulinemic hypoglycemia in otherwise healthy individuals.

Prevalence: The estimated incidence is 1–4 cases per million persons per year worldwide, translating to roughly 3,000–12,000 new cases annually in the United States alone.<sup>1</sup> Approximately 5–10 % of insulinomas occur as part of Multiple Endocrine Neoplasia type 1 (MEN‑1) syndrome, a hereditary condition that predisposes to tumors of the pancreas, parathyroid, and pituitary glands.<sup>2</sup>

Symptoms

Symptoms stem from neuroglycopenia (brain glucose deprivation) and the body’s adrenergic response to low glucose. They may be episodic, occurring after fasting, prolonged exercise, or alcohol intake, and often improve with food.

Neuroglycopenic symptoms

• Confusion or difficulty concentrating – “brain fog” that can progress to disorientation.
• Dizziness or light‑headedness – especially when standing.
• Blurred vision – temporary visual disturbances.
• Seizures – generalized or focal, sometimes the first sign.
• Loss of consciousness – fainting or even prolonged coma in severe cases.

Adrenergic (autonomic) symptoms

• Sweating – profuse, often cold sweats.
• Tremor or shakiness – noticeable in the hands.
• Palpitations – rapid or irregular heartbeat.
• Hunger (intense) – sometimes described as “ravenous”.
• Anxiety or irritability – a feeling of “restlessness”.

Other possible features

• Headache
• Nausea
• Weakness or fatigue
• Difficulty speaking
• Behavioral changes (e.g., aggression, confusion)

Symptoms often follow a pattern known as **Whipple’s triad**: (1) symptoms of hypoglycemia, (2) documented low plasma glucose (<55 mg/dL or 3.0 mmol/L), and (3) relief of symptoms after glucose administration.<sup>3</sup>

Causes and Risk Factors

Primary cause

Insulinomas arise from genetic mutations that cause uncontrolled proliferation of β‑cells. In sporadic cases, the exact genetic trigger is unknown, though studies have identified alterations in the MEN1 gene, YY1 transcription factor, and other cell‑cycle regulators.

Risk factors

• Multiple Endocrine Neoplasia type 1 (MEN‑1) – hereditary syndrome; up to 10 % of insulinoma patients have MEN‑1.
• Family history of pancreatic neuroendocrine tumors – rare but increases suspicion.
• Age – incidence rises after 30 years.
• Sex – slight female predominance, though the reason is unclear.

There are no known lifestyle or environmental factors (smoking, diet, occupational exposure) that significantly raise risk for sporadic insulinoma.

Diagnosis

Because symptoms mimic many other conditions, a stepwise approach is used to confirm endogenous hyperinsulinemic hypoglycemia and locate the tumor.

1. Clinical assessment & Whipple’s triad

Documentation of symptoms, low plasma glucose, and symptom resolution after glucose confirms the clinical suspicion.

2. Laboratory tests

• Fasting plasma glucose – measured during a supervised 48‑ to 72‑hour fast; glucose <55 mg/dL is diagnostic.
• Insulin level – inappropriately elevated (>3 µU/mL) when glucose is low.
• C‑peptide – helps differentiate endogenous insulin production from exogenous insulin administration; levels are usually >0.6 ng/mL during hypoglycemia.
• Proinsulin – elevated (>5 pmol/L) supports insulinoma diagnosis.
• β‑hydroxybutyrate – suppressed (<2 mmol/L) during insulin‑mediated hypoglycemia.

3. Imaging to localize the tumor

1. Transabdominal ultrasound – initial, non‑invasive but limited sensitivity (≈ 30 %).
2. Contrast‑enhanced CT scan (multiphase) – detects 70–80 % of lesions; preferred first‑line imaging.
3. Magnetic resonance imaging (MRI) with gadolinium – comparable sensitivity, especially for small (<1 cm) tumors.
4. Endoscopic ultrasound (EUS) – high resolution; detects lesions as small as 2‑3 mm and permits fine‑needle aspiration.
5. Selective arterial calcium stimulation with hepatic venous sampling – used when non‑invasive imaging is negative; calcium injection stimulates insulin release from the tumor, confirming its location.
6. 68Ga‑DOTATATE PET/CT – functional imaging for neuroendocrine tumors; useful for detecting metastatic disease.

4. Pathology (post‑surgical)

If the tumor is removed, histopathology confirms the diagnosis and assesses malignancy (mitotic rate, Ki‑67 index). A Ki‑67 ≤ 2 % typically classifies the tumor as Grade 1 (low‑grade) neuroendocrine tumor.

Treatment Options

Management aims to relieve hypoglycemia, eradicate the tumor, and monitor for recurrence.

1. Surgical treatment – the definitive cure

• Enucleation – removal of the tumor alone; preferred for small (<2 cm), well‑delineated lesions not adjacent to the main pancreatic duct.
• Partial pancreatectomy (distal, central, or pancreatic head resection) – used when the tumor is large, multifocal, or near critical ducts.
• Minimally invasive approaches – laparoscopic or robot‑assisted enucleation has become standard in many centers, offering shorter hospital stays.
• Pancreaticoduodenectomy (Whipple procedure) – rarely needed; reserved for tumors in the pancreatic head with suspicion of invasion.

2. Medical management (for unresectable or metastatic disease)

• Diazoxide – oral potassium channel activator that suppresses insulin release; dose 3–10 mg/kg/day divided 2–3 times.<sup>4</sup>
• Somatostatin analogues (octreotide, lanreotide) – bind somatostatin receptors on the tumor, decreasing insulin output; useful especially in metastatic or MEN‑1 cases.
• Everolimus – mTOR inhibitor; shown to stabilize disease in advanced pancreatic neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT) – delivers targeted radiation to somatostatin‑receptor‑positive tumors; reserved for progressive metastatic disease.

3. Acute hypoglycemia control

• Immediate ingestion of fast‑acting carbohydrate (e.g., 15 g glucose tablets) or IV dextrose 50 % if the patient is unconscious.
• Glucagon injection (1 mg intramuscular) if IV access is unavailable.

4. Lifestyle adaptations (adjunct to medical therapy)

• Frequent small meals with balanced macronutrients.
• Avoid prolonged fasting; include protein at each snack to blunt insulin spikes.
• Limit alcohol, which impairs gluconeogenesis.

Living with Insulinoma

Even after successful surgery, long‑term follow‑up is essential because up to 10 % of apparently benign insulinomas recur.

Monitoring

• Schedule abdominal imaging (CT or MRI) every 6–12 months for the first 3 years, then annually.
• Check fasting glucose and insulin levels periodically, especially if symptoms reappear.

Daily management tips

1. Carry emergency glucose – tablets, gel, or a small snack at all times.
2. Wear a medical alert bracelet indicating “Insulinoma – prone to hypoglycemia”.
3. Educate family, friends, and coworkers on how to recognize hypoglycemia and administer glucose or glucagon.
4. Maintain a symptom‑log – record timing of episodes, meals, and glucose readings; this helps the care team adjust treatment.
5. Exercise wisely – check glucose before, during, and after activity; have carbs ready.
6. Limit stress and adequate sleep – both can affect glucose regulation.

Psychological support

Living with an unpredictable “hypoglycemia‑phobia” can cause anxiety. Cognitive‑behavioral therapy, support groups, or counseling are beneficial, and many centers offer specialized endocrine‑psychology services.

Prevention

Because most insulinomas are sporadic and not linked to modifiable risk factors, primary prevention is limited. However, the following measures can help early detection in at‑risk groups:

• Genetic counseling and testing for individuals with a family history of MEN‑1 or other pancreatic neuroendocrine tumors.
• Regular surveillance (annual fasting glucose and, if indicated, imaging) for known MEN‑1 carriers.
• Adopt a healthy lifestyle (balanced diet, regular exercise) to support overall pancreatic health, though evidence for direct prevention is indirect.

Complications

If an insulinoma is left untreated or if a malignant tumor spreads, several serious complications may arise:

• Severe, recurrent hypoglycemia – can cause permanent neurologic injury, seizures, or coma.
• Accidents or injuries – sudden loss of consciousness may lead to falls, motor vehicle crashes, or occupational hazards.
• Malignant transformation – 5–10 % of insulinomas become metastatic (most commonly to liver and lymph nodes).
• Pancreatitis – rare, may occur after surgical manipulation.
• Pancreatic insufficiency – after extensive resection, patients can develop exocrine insufficiency (steatorrhea) or new‑onset diabetes.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. “Insulinoma.” Updated 2023. https://www.mayoclinic.org
2. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Multiple Endocrine Neoplasia Type 1.” 2022. https://www.niddk.nih.gov
3. American Diabetes Association. “Hypoglycemia (Low Blood Glucose).” 2024. https://diabetes.org
4. Wang TS, et al. “Diazoxide in the treatment of hyperinsulinemic hypoglycemia.” J Clin Endocrinol Metab. 2021;106(3):789‑795.
5. Cleveland Clinic. “Pancreatic Neuroendocrine Tumors – Diagnosis & Treatment.” 2023. https://my.clevelandclinic.org

```